WeightWatchers to offer compounded version of Novo Nordisk's weight-loss drug
Adds background on telehealth companies in paragraph 3, price in paragraph 5
Oct 8 (Reuters) -WeightWatchers WW.O said on Tuesday it would offer a compounded version of Novo Nordisk's NOVOb.CO popular obesity drug Wegovy as part of its weight-management programs.
Soaring demand for weight-loss drugs such as Wegovy and Eli Lilly's LLY.N Zepbound, shown to help patients lose as much as 20% of weight on average, has led to their shortages that allowed drug compounders to produce them under U.S. regulations.
Multiple telehealth companies, including Noom and Hims & Hers Health HIMS.N, offer compounded versions of semaglutide, the chemical name of Novo's Wegovy and its diabetes drug Ozempic, as patients look for alternatives amid their shortage.
Drug compounding refers to the practice of combining, mixing or altering drug ingredients to create a medicine tailored for an individual patient's need, according to the U.S. Food and Drug Administration.
The company, also known as WW International, said the new offering would start at $129.
Its shares were up 3.8% in late-morning trading, paring early gains.
"Given the ongoing shortages of branded medications such as Ozempic and Wegovy, WeightWatchers is committed to ensuring our members still have access to effective alternatives," CEO Tara Comonte said in a statement.
Outsourcing Facilities Association, a drug compounding industry group, sued the FDA on Monday over its decision to take Eli Lilly's blockbuster weight-loss and diabetes drugs off its list of medicines in short supply last week.
Novo's Wegovy and Ozempic are still on that list.
The compounding group claimed the FDA removed Lilly's tirzepatide, the key ingredient in its drugs Mounjaro and Zepbound, from the list even though it remains in short supply.
Lilly said in August it had begun selling vials of its Zepbound at $399 for a month's supply through its direct-to-consumer website.
Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
